Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24303704 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TSHRNPSR1GRIA1CYP2C9 | |
| SCHEMBL3161747 | 0.78 | GRIA1 (0.58) | ALDH1A1TSHRNPSR1GRIA1CYP2C9 | |
| SCHEMBL28219948 | 0.74 | GRIA1 (0.35) | GRIA1CA1 | |
| SCHEMBL24303319 | 0.73 | GRIA1 (0.42) | TSHRGRIA1CYP2C19CA1 | |
| SCHEMBL9612083 | 0.69 | TP53 (0.35) | GRIA1CA1 | |
| SCHEMBL3151454 | 0.69 | ALDH1A1 (0.60) | ALDH1A1TSHRNPSR1CYP2C9CYP2C19 | |
| SCHEMBL3156232 | 0.68 | ALDH1A1 (0.54) | ALDH1A1TSHRNPSR1CYP2C9CYP2C19 | |
| SCHEMBL20053716 | 0.68 | ALDH1A1 (0.44) | ALDH1A1TSHRNPSR1GRIA1CYP2C9 | |
| SCHEMBL12425770 | 0.67 | CA1 (0.50) | GRIA1CA1 | |
| SCHEMBL12448143 | 0.67 | GRIA1 (0.65) | ALDH1A1TSHRGRIA1GAADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | ALDH1A1 3918/4885TSHR 542/4885NPSR1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.